The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Biomedica Regulatory News (OXB)

Share Price Information for Oxford Biomedica (OXB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 228.50
Bid: 228.50
Ask: 231.00
Change: 8.50 (3.86%)
Spread: 2.50 (1.094%)
Open: 222.00
High: 234.00
Low: 221.00
Prev. Close: 220.00
OXB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

2023 AGM Notification

5 May 2023 07:00

RNS Number : 4997Y
Oxford Biomedica PLC
05 May 2023
 

Oxford Biomedica PLC

2023 AGM Notification

London, UK - 5 May 2023: Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica", "the Company" or "the Group"), a quality and innovation-led viral vector CDMO, gives notice that the Notice of Annual General Meeting ("AGM") together with a copy of the 2022 Annual report and accounts are being sent to shareholders today. These documents are available on the "Investors" section of the Group's website at www.oxb.com.

In accordance with Listing rule 9.6.1, a copy of the Notice of AGM has been submitted to the Financial Conduct Authority for publication through the National Storage Mechanism and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.The Company intends to hold its AGM on Friday 23 June 2023 at the offices of Oxford Biomedica, Windrush Court, Transport Way, Oxford OX4 6LT, commencing at 3:00 p.m.

 

For further information, please contact:

 

Oxford Biomedica plc:

Natalie Walter, Company Secretary

 

Tel: +44 (0)1865 783 000

 

Notes for editors

 

Oxford Biomedica (LSE: OXB) is a quality and innovation-led viral vector CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

 

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica's world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.

 

Oxford Biomedica, a FTSE4Good constituent, is headquartered in Oxford, UK. It has locations across Oxfordshire, UK and a US-based subsidiary, Oxford Biomedica Solutions, based near Boston, MA, US. Learn more at www.oxb.com, www.oxbsolutions.com, and follow us on LinkedIn, Twitter and YouTube.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NOAUSAKROUUVRAR
Date   Source Headline
2nd Apr 20247:00 amRNSTotal Voting Rights
20th Mar 20247:00 amRNSUpdate on CDMO Services
11th Mar 20247:00 amRNSBoard Changes
5th Mar 20247:00 amRNSUpdated Financial Guidance and 2023 Trading
1st Mar 20247:00 amRNSTotal Voting Rights
15th Feb 20247:00 amRNSAppointment of Joint Corporate Broker
1st Feb 20244:48 pmRNSHolding(s) in Company
1st Feb 20247:00 amRNSTotal Voting Rights
31st Jan 20247:00 amRNSBlock Listing Application
30th Jan 20247:00 amRNSTotal Voting Rights
29th Jan 20248:38 amRNSCompletion of Transaction
26th Jan 20243:09 pmRNSBlock listing application
4th Jan 202411:49 amRNSDirector Declaration
2nd Jan 20247:00 amRNSBlock Listing Return
2nd Jan 20247:00 amRNSTotal Voting Rights
13th Dec 20237:00 amRNS2023 AGM Post Meeting Update Statement
7th Dec 20237:00 amRNSBusiness Update
4th Dec 20237:00 amRNSSigning of agreement to acquire ABL Europe
1st Dec 20237:00 amRNSTotal Voting Rights
24th Nov 20237:00 amRNSGrant of options
16th Nov 20233:32 pmRNSPDMR Dealing – Replacement
14th Nov 20231:43 pmRNSPDMR Dealings
1st Nov 20237:00 amRNSTotal Voting Rights
24th Oct 20236:17 pmRNSHolding(s) in Company
24th Oct 20235:36 pmRNSHolding(s) in Company
16th Oct 20237:00 amRNSHolding(s) in Company
13th Oct 20237:00 amRNSHolding(s) in Company
11th Oct 202311:33 amRNSPDMR Dealings
4th Oct 20235:09 pmRNSGrant of Options
2nd Oct 20233:06 pmRNSTotal Voting Rights
27th Sep 202312:03 pmRNSPDMR / PCA Dealing
26th Sep 20233:47 pmRNSPDMR Dealings
22nd Sep 202311:42 amRNSPDMR Dealings
20th Sep 202311:42 amRNSDirector Dealings
20th Sep 20237:01 amRNSProject Aquarius
20th Sep 20237:00 amRNSInterim results
1st Sep 20237:00 amRNSTotal Voting Rights
22nd Aug 20237:00 amRNSExpanded agreement with Cabaletta Bio
14th Aug 20237:00 amRNSNotice of Interim Results
1st Aug 20237:00 amRNSTotal Voting Rights
3rd Jul 20234:31 pmRNSPDMR Dealings
3rd Jul 20237:00 amRNSOxford Biomedica PLC - Block Listing Return
3rd Jul 20237:00 amRNSTotal Voting Rights
23rd Jun 20235:32 pmRNSResult of AGM
6th Jun 20233:59 pmRNSTotal Voting Rights
15th May 20237:00 amRNSOxford Biomedica launches TetraVecta system
10th May 20237:00 amRNSBlock listing Application
5th May 20237:00 amRNS2023 AGM Notification
2nd May 20237:00 amRNSTotal Voting Rights
28th Apr 20237:59 amRNS2022 Annual Report and Accounts

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.